Dexmedetomidine sedation in ICU
Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor agonist, is the newest agent introduced for sedation in intensive care unit (ICU). The sedation strategy for critically ill patients has stressed light sedation with daily awakening and assessment for neurologic, cognitive, and respira...
Main Author: | Soo-Bong Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society of Anesthesiologists
2012-05-01
|
Series: | Korean Journal of Anesthesiology |
Subjects: | |
Online Access: | http://ekja.org/upload/pdf/kjae-62-405.pdf |
Similar Items
-
Dexmedetomidine for sedation in intensive care. Literature review and clinical experience
by: Dmytro Dmytriiev, et al.
Published: (2020-06-01) -
Effects of dexmedetomidine on delirium duration of non-intubated ICU patients (4D trial): study protocol for a randomized trial
by: Clémence Louis, et al.
Published: (2018-06-01) -
Dexmedetomidine versus Propofol Sedation for Prevention of Postoperative Delirium: Clarifications Required [Letter]
by: Deng J, et al.
Published: (2021-07-01) -
Comparison between dexmedetomidine and propofol as sedatives for critically ill patients in intensive care units
by: Sabah N. AL-Saad, et al.
Published: (2018-04-01) -
Dexmedetomidine Based Sedation for Post-surgery Critically Ill Adults: A Meta-analysis of Randomized Controlled Trials
by: Heng FAN, et al.
Published: (2017-11-01)